Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics

Study Overview
=================
Brief Summary
-----------------
This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.

Detailed Description
-----------------
Sensitivity for prediction recurrence and survival of currently available prognostic scores is limited. This study proposes to establish a multimodal radiomics model for identifying tumor recurrence and prognostic prediction of spinal tumors. The study will investigate the relationship between the radiomics and the tumor microenvironment. The study includes the construction of multimodal radiomics-based prediction model and the validation of the prediction model.

Official Title
-----------------
Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics

Conditions
-----------------
Stereotactic Radiosurgery, Spinal Tumor, Radiomics, Prognosis

Intervention / Treatment
-----------------
* Other: No interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status >60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age >18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery Exclusion Criteria: Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed. Subjects with spinal cord compression; minimally invasive separation surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| spinal tumors, CT, MRI, PET-CT stereotactic radiosurgery<br>Patients who had spinal tumors and completed the CT, MRI or PET-CT examination before and after stereotactic radiosurgery. | Other: No interventions<br>* As this is a prognosis evaluation study, there are no interventions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | progression-free survival | 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | defined as the time from the beginning of diagnosis of spinal tumors to the death with any causes | 1 years | 
| ORR | objective response rate | 3 months | 
| DCR | disease control rate | 3 months | 
| Recurrence free survival (RFS) | defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred | 1 year |